title: Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis.
abstract: Peroxisome proliferator-activated receptor (PPAR)beta/delta-null mice exhibit enhanced tumorigenesis in a two-stage chemical carcinogenesis model as compared with wild-type mice. Previous work showed that ligand activation of PPARbeta/delta induces terminal differentiation and inhibits proliferation of primary keratinocytes, and this effect does not occur in the absence of PPARbeta/delta expression. In the present studies, the effect of ligand activation of PPARbeta/delta on skin tumorigenesis was examined using both in vivo and ex vivo skin carcinogenesis models. Inhibition of chemically induced skin tumorigenesis was observed in wild-type mice administered GW0742, and this effect was likely the result of ligand-induced terminal differentiation and inhibition of replicative DNA synthesis. These effects were not found in similarly treated PPARbeta/delta-null mice. Ligand activation of PPARbeta/delta also inhibited cell proliferation and induced terminal differentiation in initiated/neoplastic keratinocyte cell lines representing different stages of skin carcinogenesis. These studies suggest that topical administration of PPARbeta/delta ligands may be useful as both a chemopreventive and/or a chemotherapeutic approach to inhibit skin cancer.
authors.affiliation: Department of Veterinary and Biomedical Sciences and the Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, PA 16802, USA.
authors.forename: Moses T
authors.initials: MT
authors.lastname: Bility
authors.forename: Meghann K
authors.initials: MK
authors.lastname: Devlin-Durante
authors.forename: Nicholas
authors.initials: N
authors.lastname: Blazanin
authors.forename: Adam B
authors.initials: AB
authors.lastname: Glick
authors.forename: Jerrold M
authors.initials: JM
authors.lastname: Ward
authors.forename: Boo Hyon
authors.initials: BH
authors.lastname: Kang
authors.forename: Mary J
authors.initials: MJ
authors.lastname: Kennett
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Gonzalez
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Peters
mesh_terms: D000096:Acetone / Q000633:toxicity; D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D049109:Cell Proliferation / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D004789:Enzyme Activation / Q000502:physiology; D005260:Female; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008024:Ligands; D051379:Mice; D008817:Mice, Mutant Strains; D047494:PPAR delta / Q000378:metabolism*; D048068:PPAR-beta / Q000378:metabolism*; D012878:Skin Neoplasms / Q000139:chemically induced / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000633:toxicity; D013844:Thiazoles / Q000633:toxicity; D010636:Phenols; D013438:Sulfhydryl Compounds
chemical_list: D000096:Acetone; D002273:Carcinogens; D008024:Ligands; D047494:PPAR delta; D048068:PPAR-beta; D013755:Tetradecanoylphorbol Acetate; D013844:Thiazoles; C479979:(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid; D010636:Phenols; D013438:Sulfhydryl Compounds
references.citation: Mol Cell Biol. 2000 Jul;20(14):5119-28
references.pmid: 10866668
references.citation: Toxicology. 2008 Jan 14;243(1-2):236-43
references.pmid: 18054822
references.citation: Toxicol Sci. 2006 Apr;90(2):269-95
references.pmid: 16322072
references.citation: J Invest Dermatol. 2008 Feb;128(2):370-7
references.pmid: 17713572
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4312-7
references.pmid: 9113986
references.citation: Biochem Biophys Res Commun. 2008 Jul 4;371(3):456-61
references.pmid: 18442472
references.citation: Carcinogenesis. 2002 Mar;23(3):499-510
references.pmid: 11895866
references.citation: J Biol Chem. 1999 Mar 5;274(10):6718-25
references.pmid: 10037770
references.citation: Future Oncol. 2005 Jun;1(3):395-403
references.pmid: 16556013
references.citation: Carcinogenesis. 2007 Dec;28(12):2641-9
references.pmid: 17693664
references.citation: J Cell Biol. 2001 Aug 20;154(4):799-814
references.pmid: 11514592
references.citation: Anal Biochem. 1991 Nov 15;199(1):25-8
references.pmid: 1807158
references.citation: Genes Dev. 2001 Dec 15;15(24):3263-77
references.pmid: 11751632
references.citation: Exp Dermatol. 1999 Feb;8(1):71-9
references.pmid: 10206724
references.citation: Cell Death Differ. 2000 Dec;7(12):1218-24
references.pmid: 11175259
references.citation: Endocrinology. 1998 Jun;139(6):2748-54
references.pmid: 9607781
references.citation: Cancer Res. 1988 Jan 1;48(1):165-9
references.pmid: 3121168
references.citation: Curr Opin Investig Drugs. 2008 May;9(5):463-9
references.pmid: 18465655
references.citation: Endocrinology. 2003 Jun;144(6):2201-7
references.pmid: 12746275
references.citation: Curr Diab Rep. 2005 Feb;5(1):45-52
references.pmid: 15663917
references.citation: Carcinogenesis. 1986 Jun;7(6):949-58
references.pmid: 2871947
references.citation: J Biol Chem. 2005 Mar 11;280(10):9519-27
references.pmid: 15632134
references.citation: J Invest Dermatol. 2004 Apr;122(4):971-83
references.pmid: 15102088
references.citation: J Biol Chem. 2007 Jul 6;282(27):19313-20
references.pmid: 17500064
references.citation: Endocr Rev. 1999 Oct;20(5):649-88
references.pmid: 10529898
references.citation: Dev Dyn. 1994 Mar;199(3):176-88
references.pmid: 7517223
references.citation: Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):359-65
references.pmid: 17110604
references.citation: J Exp Med. 2007 Sep 3;204(9):2053-61
references.pmid: 17724132
references.citation: Nature. 1981 Sep 3;293(5827):72-4
references.pmid: 6791032
references.citation: Cell Death Differ. 2006 Jan;13(1):53-60
references.pmid: 16021179
references.citation: J Biol Chem. 2004 May 28;279(22):23719-27
references.pmid: 15033975
references.citation: Biochimie. 2004 Nov;86(11):833-7
references.pmid: 15589693
references.citation: Endocrinology. 1996 Jan;137(1):354-66
references.pmid: 8536636
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3444-9
references.pmid: 16492734
references.citation: Semin Thromb Hemost. 2004 Feb;30(1):31-44
references.pmid: 15034796
references.citation: Clin Sci (Lond). 2008 Aug;115(4):107-27
references.pmid: 18616431
references.citation: FEBS Lett. 2000 May 19;473(3):333-6
references.pmid: 10818235
references.citation: Pathophysiol Haemost Thromb. 2006;35(1-2):103-10
references.pmid: 16855354
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5306-11
references.pmid: 11309497
references.citation: Cancer Res. 1990 Aug 1;50(15):4794-800
references.pmid: 2114947
references.citation: Biochim Biophys Acta. 2003 Jul 4;1633(1):43-50
references.pmid: 12842194
references.citation: Environ Health Perspect. 1986 Sep;68:91-104
references.pmid: 3780637
references.citation: Bioorg Med Chem Lett. 2003 May 5;13(9):1517-21
references.pmid: 12699745
references.citation: Curr Biol. 1999 Apr 8;9(7):361-4
references.pmid: 10209121
references.citation: Hamostaseologie. 2005 Nov;25(4):380-6
references.pmid: 16395488
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15924-9
references.pmid: 14676330
references.citation: Cell Signal. 2006 Jan;18(1):9-20
references.pmid: 16109478
references.citation: Cell Signal. 2007 Jun;19(6):1163-71
references.pmid: 17254750
references.citation: Cancer Res. 2002 Jun 15;62(12):3395-401
references.pmid: 12067981
references.citation: Biochimie. 2005 Jan;87(1):5-8
references.pmid: 15733729
references.citation: Carcinogenesis. 1980;1(12):995-1006
references.pmid: 11272116
references.citation: J Invest Dermatol. 2001 May;116(5):702-12
references.pmid: 11348458
references.citation: Cell. 2003 Apr 18;113(2):159-70
references.pmid: 12705865
references.citation: Cancer Res. 1980 Dec;40(12):4694-703
references.pmid: 7438101